First Horizon Announces Update on Cardiovascular Product

    Pharmaceutical Writers/Business Editors

    ALPHARETTA, Ga.--(BUSINESS WIRE)--Jan. 3, 2005--As previously announced, First Horizon Pharmaceutical Corporation (NASDAQ: FHRX) and SkyePharma PLC (LSE: SKP) (NASDAQ: SKYE) have entered into an exclusive U.S. marketing and distribution arrangement granting First Horizon rights to sell a cardiovascular product, now disclosed as a fenofibrate-based product, that has been submitted to the US Food & Drug Administration ("FDA") for approval. The parties had expected that the FDA would approve the product by December 31, 2004; however, SkyePharma has received an approvable letter from the FDA requesting additional information from SkyePharma with respect to the fenofibrate product. As a result, the parties have renegotiated their arrangement extending the contract date for FDA approval to January 31, 2005.

    First Horizon Background

    First Horizon Pharmaceutical Corporation is a specialty pharmaceutical company that markets and sells prescription products with a primary focus on cardiology and women's health/pediatrics. First Horizon has a portfolio that includes 14 branded prescription products of which 6 are actively promoted to high-prescribing physicians through its nationwide marketing and sales force of approximately 360 representatives. First Horizon's web site address is: http://www.fhrx.com. Please visit First Horizon's website for full prescribing information on First Horizon's products.

--30--TS/ch*

CONTACT: First Horizon Pharmaceutical Corporation Darrell Borne, 770-442-9707, ext. 6530 ir@fhrx.com

KEYWORD: GEORGIA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY PRODUCT MARKETING AGREEMENTS SOURCE: First Horizon Pharmaceutical Corporation

Copyright Business Wire 2005